Compare LPA & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LPA | EQ |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.1M | 129.0M |
| IPO Year | 2023 | 2018 |
| Metric | LPA | EQ |
|---|---|---|
| Price | $3.43 | $2.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 16.3K | ★ 267.6K |
| Earning Date | 05-13-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.04 | $0.29 |
| 52 Week High | $9.41 | $2.70 |
| Indicator | LPA | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 50.79 | 52.20 |
| Support Level | $3.05 | $1.60 |
| Resistance Level | $3.80 | $2.42 |
| Average True Range (ATR) | 0.29 | 0.20 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 38.45 | 34.33 |
Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has four operating segments, based on geographic regions, consisting of Colombia, Peru, Mexico and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.